Perpetual Ltd Has $10.53 Million Position in Medtronic PLC $MDT

Perpetual Ltd raised its holdings in Medtronic PLC (NYSE:MDT) by 50.1% during the third quarter, HoldingsChannel reports. The firm owned 110,520 shares of the medical technology company’s stock after acquiring an additional 36,896 shares during the quarter. Perpetual Ltd’s holdings in Medtronic were worth $10,526,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in MDT. 1248 Management LLC bought a new stake in Medtronic in the 1st quarter valued at about $26,000. Delos Wealth Advisors LLC bought a new position in shares of Medtronic in the second quarter worth $27,000. Twin Tree Management LP bought a new stake in shares of Medtronic during the 1st quarter valued at $29,000. Activest Wealth Management boosted its stake in Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 322 shares during the period. Finally, GFG Capital LLC purchased a new position in Medtronic during the 2nd quarter valued at about $36,000. 82.06% of the stock is owned by institutional investors.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic filed an S-1 to take its Diabetes unit, MiniMed, public — the preferred separation path is an IPO followed by a split-off. Management says the move is part of a planned separation aimed at creating two focused companies, which could unlock value and provide strategic clarity. Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed
• Positive Sentiment: Regulatory and product progress: Medtronic (and peers) secured FDA nods for liquid embolic systems — a reminder the company continues to advance therapeutic devices that can support organic growth beyond the diabetes separation. Medtronic, J&J MedTech both get FDA nods for liquid embolic systems
• Neutral Sentiment: Ownership and structure details may limit immediate financial impact — media reports note Medtronic expects to retain majority voting control (reported at least ~80.1% of voting stock), suggesting the IPO could be more about strategic focus and value crystallization than a full divestiture. Medtronic Spin-Off MiniMed Files for IPO
• Neutral Sentiment: Analyst stances remain cautious: some firms (e.g., Robert W. Baird) are maintaining “hold” ratings, reflecting mixed near-term views even as the strategic move unfolds. Robert W. Baird Remains a Hold on Medtronic (MDT)
• Negative Sentiment: Price-target trim: Truist cut its MDT price target modestly (from $110 to $107) and kept a “hold” rating, a sign some analysts see limited near-term upside despite the strategic separation. This analyst action could cap momentum until clearer financials for MiniMed and separation mechanics are disclosed. Medtronic price target lowered to $107 from $110 at Truist

Medtronic Stock Up 0.2%

MDT opened at $98.63 on Friday. The firm’s 50 day simple moving average is $97.38 and its two-hundred day simple moving average is $93.41. The company has a market capitalization of $126.45 billion, a PE ratio of 26.59, a PEG ratio of 2.60 and a beta of 0.71. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $106.33. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the business posted $1.26 earnings per share. The business’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price target on shares of Medtronic in a report on Wednesday, November 19th. UBS Group upped their price objective on Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a report on Wednesday, November 19th. Wells Fargo & Company boosted their target price on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Argus raised their target price on shares of Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, August 26th. Finally, Daiwa Capital Markets increased their target price on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $109.94.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).